|
|
|
Abstract Objective: To evaluate the clinical outcomes of letrozolecombined with human menopausal gonadotropin(LE+HMG)using for ovulation induction in patients with Polycystic ovary syndrome （PCOS）, and LE+HMG was compare with HMC only. Methods: Database such as CNKI, VIP, Wanfang, CBMdisc, PubMed, and Cochrane Library were searched with no limited language and publication time. The relevant printed medical journals and periodicals were also hand searched. Only randomized controlled trials (RCT) were included for meta-analysis. Two reviewers searched and assessed articles quality independently. RevMan5.3 was used for analysis. Results: 7 RCTs were involved, which were including 601 women and 688 cycles. When compared LE+HMG with HMG only, The dosage of HMG when LE+HMG using was lower than that of HMG using only［MD=-3.64，95% CI(-7.20，-0.08)，P=0.04］, and the number of dominant follicles were significant less of LE+HMG than that of using HMG only，［-1.33，95% CI(-2.33，-0.33)，P=0.01］. But there were no significant differences on pregnancy rate, adverse event incidence, and the endometrial thickness on the day of hCG injection，［RR=1.05，95% CI(0.74，1.50)，P=0.78］；［RD=-0.03，95%CI（-0.07，0.02），P=0.22］；［MD=-0.21，95%CI（-0.82，0.40），P=0.51］. Conclusion: LE+HMG not only had the similar pregnancy rate compared with that of HMG only, but also reduced the dosage of HMG it maybe relieve the economical burden of patients.
|
|
|
|
|
|
|
|
